The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market size is expected to surpass an impressive valuation of US$ 809 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033 to be valued at US$ 1,448.75 Million.
Clostridium difficile infection (CDI) is an illness caused by toxic substances generated by the "Clostridium difficile" spore-forming bacteria living in the big intestine. It belongs to the closely connected causal factors of antibiotic-related diarrhea, with signs ranging from mild, self-limiting diarrhea to chronic diarrhea, pseudomembranous colitis, and potentially fatal fulminant colitis. Antimicrobial drug consumption is predicted to drive expansion in the Clostridium difficile infection therapeutics market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | US$ 801 Million |
| Market Value (2023) | US$ 809 Million |
| Anticipated Forecast Value (2033) | US$ 1,448.75 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Over the historical era, the difficile infection treatment market was influenced by the increasing incidence of clostridium-related illness and the growing worldwide aging population. Growing urbanization, an advanced healthcare system, and innovative technologies also enhanced market growth in the past years.
The aging global population is projected to propel the Clostridium Clostridium Difficile Infection Treatment market throughout the forecast period. Furthermore, modern lifestyles, advanced healthcare systems, and technological developments are predicted to propel market growth over the next several years. Also, the widespread use is expected to accelerate the expansion of the worldwide clostridium difficile infection treatment market.
Furthermore, the COVID-19 pandemic had a brief influence on the Clostridium Difficile Infection Therapeutics Market, as sales dropped during the virus's outbreak in 2020 due to massive losses in lifestyles and the global economy. Nevertheless, the industry regained following the development of vaccines and the withdrawal of COVID-19 restrictions.
Rising Utilization of Antibiotics to Accelerate Market Growth
Excessive drug development projects for creating and marketing new drugs are estimated to drive growth in the clostridium difficile infection treatment market by offering therapists a new therapeutic option. Moreover, the introduction of a new class of non-antibiotic medications and vaccines is expected to provide a plethora of possibilities for market participants while also growing the competitiveness for developing novel drugs as superior therapeutic approaches. As a result, higher drug programs for novel drugs to improve treatment and prevention are expected to propel the market's growth in the coming years.
Rising Utilization of Antibiotics accelerates Market Growth
Long-term antibiotic consumption is the most common cause of Clostridium difficile infection. Antibacterial drugs use changes the colorectal bacteria, enabling Clostridium difficile bacteria to thrive. Cephalosporins, clindamycin, and quinolone antibiotics seem to be more susceptible to causing Clostridium difficile infection (CDI).
The elevated utilization of these antibiotics is expanding the likelihood of Clostridium difficile infection, which is predicted to boost the requirement for its treatments. As a result, increased antibiotic usage is an important driver of expansion in the worldwide clostridium difficile infection treatment market.
Principal Consultant
Substantial Investments Required for Drug Development to restrict the market growth
Antibiotics are the only ongoing effective treatments for CDIs, and several pharmaceutical companies are attempting to develop non-antibiotic alternative solutions. The creation of a brand-new class of drugs will provide ample opportunities for industry participants to thrive, but it will also necessitate huge investments in novel therapy advancement and research. The significantly greater capital investments may act as a major impediment to industry growth.
Increased awareness of gastrointestinal infections drives the market growth
Because the infection is getting less prevalent, the market for clostridium difficile infection treatments is decreasing in European countries. The number of fatalities caused by healthcare-related CDI in Europe can be approximated at 3700 per year.
Because of the existence of mandatory monitoring, there has been improved compliance with isolation, personal hygiene, and cleanliness protocols, in addition to the tracking of antibiotic prescriptions. Because of greater awareness about gastrointestinal infection in the region, Europe is regarded as the second largest industry for clostridium difficile infection drugs.
An increase in suspected cases of difficile Infections (Clostridium Difficile Associated Disease) Treatment spurs the market
According to the Centers for Disease Control (CDC), clostridium difficile infects about half a million North Americans every year. Within one month of being diagnosed with C. difficile, nearly 29,000 patients died, with 15,000 of these death tolls being mainly ascribed to C. difficile infection. The Clostridium Difficile Infection industry will emerge significantly in the next few years as healthcare expenditure in this region rises, suspected cases of Clostridium difficile infection (CDI) increase and forthcoming treatments are anticipated to be launched.
With developments in molecular biology methods over the last two decades, there have been numerous advancements in comprehending the genetic variety, evolution, and pathogenicity of Clostridium difficile. In North America, recurring clinical and academic activities are anticipated to continue to resolve impediments in the coming decades. Furthermore, the United States had the highest proportion of Clostridium difficile infection, accounting for nearly 70% of all cases reported of Clostridium difficile infection worldwide.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The antibiotic segment is projected to expand quickly
Recently, standard antibiotics such as metronidazole, Vancomycin, and Fidaxomicin have been employed to cure Clostridium difficile infection (CDI). Presently, there are no alternatives to antibiotics for the treatment of Clostridium difficile infection, and surgical procedure remains the only option (in severe cases). As a result, the antibiotic segment is expected to grow rapidly over the forecast timeframe.
A rise in the number of hospitalized patients drives the market growth
The end-user market is dominated by the hospital segment. This, coupled with an increase in hospitalized patients and a greater focus on public health agencies, is anticipated to propel Hospital segment expansion during the forecast period.
Key players in the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market are Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.
| Report Attribute | Details |
|---|---|
| Market Value (2023) | US$ 809 Million |
| Anticipated Forecast Value (2033) | US$ 1,448.75 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Drug Type, End Users, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, BENELUX, Germany, The UK, France, Spain, Italy, Nordics, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Merck & Co. Inc.; Baxter International Inc.; Sanofi S.A; Pfizer Inc.; Novartis AG; Astellas Pharma; Eli Lily & Company; AstraZeneca; Actelion Pharmaceuticals Ltd.; Mylan N.V |
| Customization | Available Upon Request |
FMI projects the global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market to expand at a 6% value CAGR by 2033.
The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is estimated at a market value of US$ 809 Million.
The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is expected to garner a market value of US$ 1,448.75 Million.
FMI has projected North America to be one of the key regions for the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market.
Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, AstraZeneca Plc.
1. Executive Summary | Difficile Infections (Clostridium Difficile Associated Disease) Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Antimicrobial Therapy 5.3.2. Faecal Microbiota Transplantation 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 6.3.1. Metronidazole 6.3.2. Vancomycin 6.3.3. Fidaxomicin 6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033 7.3.1. Hospital 7.3.2. Pharmacies 7.3.3. ASCs 7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia-Pacific 8.3.6. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The US 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Drug Type 9.2.4. By End Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Drug Type 9.3.4. By End Users 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Drug Type 10.2.4. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Drug Type 10.3.4. By End Users 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Benelux 11.2.1.2. France 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. Nordic 11.2.1.6. Spain 11.2.1.7. The UK 11.2.1.8. Rest of Western Europe 11.2.2. By Treatment 11.2.3. By Drug Type 11.2.4. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Drug Type 11.3.4. By End Users 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Rest of Eastern Europe 12.2.2. By Treatment 12.2.3. By Drug Type 12.2.4. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Drug Type 12.3.4. By End Users 12.4. Key Takeaways 13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Australia 13.2.1.6. New Zealand 13.2.1.7. Rest of APAC 13.2.2. By Treatment 13.2.3. By Drug Type 13.2.4. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Drug Type 13.3.4. By End Users 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment 14.2.3. By Drug Type 14.2.4. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Drug Type 14.3.4. By End Users 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. The US 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment 15.1.2.2. By Drug Type 15.1.2.3. By End Users 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment 15.2.2.2. By Drug Type 15.2.2.3. By End Users 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment 15.3.2.2. By Drug Type 15.3.2.3. By End Users 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment 15.4.2.2. By Drug Type 15.4.2.3. By End Users 15.5. Benelux 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment 15.5.2.2. By Drug Type 15.5.2.3. By End Users 15.6. France 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment 15.6.2.2. By Drug Type 15.6.2.3. By End Users 15.7. Germany 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment 15.7.2.2. By Drug Type 15.7.2.3. By End Users 15.8. Italy 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment 15.8.2.2. By Drug Type 15.8.2.3. By End Users 15.9. Nordic 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment 15.9.2.2. By Drug Type 15.9.2.3. By End Users 15.10. Spain 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment 15.10.2.2. By Drug Type 15.10.2.3. By End Users 15.11. The UK 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment 15.11.2.2. By Drug Type 15.11.2.3. By End Users 15.12. Poland 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment 15.12.2.2. By Drug Type 15.12.2.3. By End Users 15.13. Russia 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment 15.13.2.2. By Drug Type 15.13.2.3. By End Users 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment 15.14.2.2. By Drug Type 15.14.2.3. By End Users 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment 15.15.2.2. By Drug Type 15.15.2.3. By End Users 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment 15.16.2.2. By Drug Type 15.16.2.3. By End Users 15.17. Thailand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment 15.17.2.2. By Drug Type 15.17.2.3. By End Users 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment 15.18.2.2. By Drug Type 15.18.2.3. By End Users 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment 15.19.2.2. By Drug Type 15.19.2.3. By End Users 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment 15.20.2.2. By Drug Type 15.20.2.3. By End Users 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment 15.21.2.2. By Drug Type 15.21.2.3. By End Users 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Treatment 15.22.2.2. By Drug Type 15.22.2.3. By End Users 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment 16.3.3. By Drug Type 16.3.4. By End Users 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Merck & Co., Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Baxter International Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Sanofi S.A. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Pfizer Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Novartis AG 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Astellas Pharma 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Eli Lily & Company 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. AstraZeneca 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Actelion Pharmaceuticals Ltd 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Mylan N.V. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Difficile Infections (Clostridium Difficile Associated Disease) Market
